@yŠÄCz
@•lŒE@—²—Y@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •ªŽq¶•¨ˆãŠw ‹³Žö
@y•ÒWˆÏˆõ’·z
@’Ö{@_•½@“Œ‹ž‘åŠw ˆã‰ÈŠwŒ¤‹†Š Ž¾Š³ƒvƒƒeƒIƒ~ƒNƒXƒ‰ƒ{ƒ‰ƒgƒŠ[ ‹³Žö
@y•ÒWˆÏˆõzi50‰¹‡j
@ŠÞ‘q@³Š°@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ƒoƒCƒIƒƒfƒBƒJƒ‹Œ¤‹†•”–å µãÙŒ¤‹†ˆõ
@‰ª•”@®•¶@’†ŠO»–òiŠ”j Ž·s–ðˆõ Œ¤‹†–{•”’·
@’ÑA@ˆèÆ@“¡“c•ÛŒ’‰q¶‘åŠw ˆãŠw•” ¬Ž™‰ÈŠw‹³Žº ‹³Žö
@–쑺@•¶•v@ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ •ªŽq•a‘Ô‰ðÍŠw ‹³Žö
@yŽ·•MŽÒz135–¼@
@•lŒE@—²—Y@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •ªŽq¶•¨ˆãŠw ‹³Žö
@’Ö{@_•½@“Œ‹ž‘åŠw ˆã‰ÈŠwŒ¤‹†Š Ž¾Š³ƒvƒƒeƒIƒ~ƒNƒXƒ‰ƒ{ƒ‰ƒgƒŠ[ ‹³Žö
@¼@@‹`‰î@’·•lƒoƒCƒI‘åŠw ‹³–±•”’· ŠwKEA‹Æ—ÍŽx‰‡‹@\’· •ªŽq¶–½‰ÈŠwƒR[ƒX’· ƒoƒCƒIƒTƒCƒGƒ“ƒXŠw•” ‹³Žö
@Šâ¬@GŽq@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •ªŽq¶•¨ˆãŠw “Á”C•‹³
@Γc@@Œ÷@’é‹ž•½¬‘åŠw –òŠw•”–òŠw‰È ‹³Žö
@‘å­@Œ’Žj@“¿“‡‘åŠw ‘åŠw‰@ƒ\ƒVƒIƒeƒNƒmƒTƒCƒGƒ“ƒXŒ¤‹†•” ƒ‰ƒCƒtƒVƒXƒeƒ€•”–åEƒtƒƒ“ƒeƒBƒAŒ¤‹†ƒZƒ“ƒ^[ ‹³Žö
@ó–ì—³‘¾˜Y@“Œ–k‘åŠw ‘åŠw‰@HŠwŒ¤‹†‰È ƒoƒCƒIHŠwêU ¶‘Ì‹@”\‰»ŠwuÀ ƒ^ƒ“ƒpƒNŽ¿HŠw•ª–ìy‹³Žö
@ŒF’J@@ò@“Œ–k‘åŠw ‘åŠw‰@HŠwŒ¤‹†‰È ƒoƒCƒIHŠwêU ‹³Žö
@“¡ˆä@ˆè—Y@‘åã•{—§‘åŠw ‘åŠw‰@—ŠwŒnŒ¤‹†‰È ¶•¨‰ÈŠwêU ¶‘Ì•ªŽq‰ÈŠw•ª–ì ‹³Žö
@‰~’J@@Œ’@‘åã•{—§‘åŠw ‘åŠw‰@—ŠwŒnŒ¤‹†‰È ¶•¨‰ÈŠwêU ¶‘Ì•ªŽq‰ÈŠw•ª–ì y‹³Žö
@’†“‡@•q”Ž@ˆê”Êà’c–@l‰»Šw‹yŒŒ´—Ö@Œ¤‹†Š ‹e’rŒ¤‹†Š‘æˆêŒ¤‹†•” •”’·
@’¹Ž”@³Ž¡@ˆê”Êà’c–@l‰»Šw‹yŒŒ´—Ö@Œ¤‹†Š ‹e’rŒ¤‹†Š‘æˆêŒ¤‹†•” ‘æ“ñŒ¤‹†Žº ㋉Œ¤‹†ˆõ
@”©’†@F²@Ž­Ž™“‡‘åŠw —HŠwŒ¤‹†‰È ƒVƒXƒeƒ€î•ñ‰ÈŠwêU ”ŽŽmŒãŠú
@ˆÉ“Œ@—S“ñ@Ž­Ž™“‡‘åŠw ‘åŠw‰@—HŠwŒ¤‹†‰È ¶–½‰»ŠwêUi—ŠwŒnj ‹³Žö
@‰Á“¡@Wˆê@‘åŠw‹¤“¯—˜—p‹@ŠÖ–@lŽ©‘R‰ÈŠwŒ¤‹†‹@\ ‰ªè“‡ƒoƒCƒIƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[^–¼ŒÃ‰®Žs—§‘åŠw ‘åŠw‰@–òŠwŒ¤‹†‰È^Š”Ž®‰ïŽÐƒOƒ‰ƒCƒGƒ“ƒX^‚¨’ƒ‚Ì…—Žq‘åŠw “œ½‰ÈŠw‹³ˆçƒZƒ“ƒ^[
@–î–Ø@G˜a@–¼ŒÃ‰®Žs—§‘åŠw ‘åŠw‰@–òŠwŒ¤‹†‰È
@‘¾Šú@Œ’“ñ@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •ªŽq¶•¨ˆãŠw “Á”C•‹³
@“nç³@áÁˆê@iŠ”jˆãŠw¶•¨ŠwŒ¤‹†Š ‹Zp¶ŽY–{•” –{•”’·‘ã—
@ûü–ì@–M•F@ƒxƒbƒNƒ}ƒ“EƒR[ƒ‹ƒ^[iŠ”j ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒeƒNƒjƒJƒ‹ƒ}[ƒPƒeƒBƒ“ƒO“Š‡•”–å ƒTƒCƒgƒƒgƒŠ[‰Û ŽåÈ
@¼‰Y@@³@iŠ”jƒyƒ‹ƒZƒEƒXƒvƒƒeƒIƒ~ƒNƒX Œ¤‹†ŠJ”­•”’·
@‰““¡@“TŽq@à’c–@l“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š ƒQƒmƒ€ˆã‰ÈŠwŒ¤‹†•ª–ì •ªŽqˆã—ÃvƒƒWƒFƒNƒg
@ŽÅú±@@‘¾@à’c–@l“Œ‹ž“sˆãŠw‘‡Œ¤‹†Š •ªŽqˆã—ÃvƒƒWƒFƒNƒg
@ˆäŒ´@–Î’j@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ “Á”C‹³Žö
@æ•l@rŽq@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ •ªŽq¶•¨ˆãŠw “Á”Cy‹³Žö
@•àV@@m@“¡“c•ÛŒ’‰q¶‘åŠw ‘‡ˆã‰ÈŠwŒ¤‹†Š R‘̃vƒƒWƒFƒNƒg•”–å^iŠ”jƒyƒ‹ƒZƒEƒXƒvƒƒeƒIƒ~ƒNƒX Œ¤‹†ŠJ”­•”
@‰LŽ”@—R”Í@“¡“c•ÛŒ’‰q¶‘åŠw ‘‡ˆã‰ÈŠwŒ¤‹†Š R‘̃vƒƒWƒFƒNƒg•”–å^iŠ”jƒyƒ‹ƒZƒEƒXƒvƒƒeƒIƒ~ƒNƒX Œ¤‹†ŠJ”­•”
@ç—t@@ä@“Œ‹ž—‰È‘åŠw Šî‘bHŠw•”¶•¨HŠw‰È –ƉuE–ƉuHŠwŒ¤‹†Žº ‹³Žö
@‚’Ë@ãÄŒá@“Œ‹ž—‰È‘åŠw ¶–½ˆã‰ÈŠwŒ¤‹†Š •ªŽq¶•¨ŠwŒ¤‹†•”–å •‹³
@“¡–{@@—z@“Œ‹ž—‰È‘åŠw Šî‘bHŠw•”¶•¨HŠw‰È –ƉuE–ƉuHŠwŒ¤‹†Žº •‹³
@ãŒû@ŒO—Y@ŒF–{‘åŠw ‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•” Š´õE–ƉuŠwuÀ –ƉuŠw•ª–ì
@‘O“c@˜a•F@ŒF–{‘åŠw ‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•” Š´õE–ƉuŠwuÀ –ƉuŠw•ª–ì
@ŒKŒ´@ˆê•F@ŒF–{‘åŠw ‘åŠw‰@¶–½‰ÈŠwŒ¤‹†•” Š´õE–ƉuŠwuÀ –ƉuŠw•ª–ì
@‹àX@@’@ƒW[ƒ“ƒtƒƒ“ƒeƒBƒAiŠ”j Ž–‹ÆŠJ”­•” •”’· Œ¤‹†ŠJ”­•” •›•”’·
@ã“c@‘ì–ç@“Œ‹ž‘åŠw ‘åŠw‰@V—̈æ‘n¬‰ÈŠwŒ¤‹†‰È Œ¤‹†‰È’· ƒƒfƒBƒJƒ‹ƒQƒmƒ€êU ‹³Žö
@£”ö@G@@iŠ”jƒJƒCƒIƒ€EƒoƒCƒIƒTƒCƒGƒ“ƒX Œ¤‹†Šé‰æ„i•” ƒVƒjƒAƒfƒBƒŒƒNƒ^[
@‹´–{@Cˆê@iŠ”jƒJƒCƒIƒ€EƒoƒCƒIƒTƒCƒGƒ“ƒX Ž–‹Æ–{•” ƒVƒjƒAƒŠƒT[ƒ`ƒƒ[
@¼“c@Ž¡’j@L“‡‘åŠw ‘åŠw‰@¶•¨Œ—‰ÈŠwŒ¤‹†‰È “Á”C‹³Žö
@‘•Û@ˆÀ•F@“Œ‹ž—‰È‘åŠw –òŠw•”
@‹àŽq@@—v@“Œ‹ž—‰È‘åŠw –òŠw•”
@Ε@@—º@“Œ‹ž‘åŠw ˆã‰ÈŠwŒ¤‹†Š Šî‘bˆã‰ÈŠw•”–å ˆâ“`Žq“®‘Ô•ª–ì •‹³
@’†‘º@‹`ˆê@“Œ‹ž‘åŠw ˆã‰ÈŠwŒ¤‹†Š Šî‘bˆã‰ÈŠw•”–å ‹³Žö
@‹àŽq@’¼Ž÷@iŠ”j“‡’Ã»ìŠ “c’†Åæ’[Œ¤‹†Š Œ¤‹†ŠJ”­‘æ2 ƒOƒ‹[ƒv
@‹gX@Fs@iŠ”j“‡’Ã»ìŠ “c’†Åæ’[Œ¤‹†Š
@“ˆ“c@’Žj@iŠ”j“‡’Ã»ìŠ “c’†Åæ’[Œ¤‹†Š
@Daniel J. Capon@ Blood Systems Research Institute, CA, USA
@“c’†@kˆê@iŠ”j“‡’Ã»ìŠ “c’†Åæ’[Œ¤‹†Š
@²“¡@F–¾@iŠ”j“‡’Ã»ìŠ “c’†Åæ’[Œ¤‹†Š
@Žáˆä@ƒŽq@Ž­Ž™“‡‘åŠw ‘åŠw‰@—HŠwŒ¤‹†‰È ƒVƒXƒeƒ€î•ñ‰ÈŠwêU ”ŽŽmŒãŠú
@”‹Œ´@‹`‹v@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š Œ’NHŠwŒ¤‹†•”–å Œ¤‹†ƒOƒ‹[ƒv’·
@‹{ú±@½¶@ƒA[ƒNEƒŠƒ\[ƒXiŠ”j Ž–‹Æ„iŽº Žº’·
@ìŒû@”Ž–¾@Ž­Ž™“‡‘åŠw ‹¤“¯bˆãŠw•” bˆãŠw‰È •a‘Ô—\–hbŠwuÀ ‘gD•a—Šw•ª–ì y‹³Žö
@¬“‡@•q”V@Ž­Ž™“‡‘åŠw ‹¤“¯bˆãŠw•” bˆãŠw‰È —Õ°bˆãŠwuÀ bˆã”ÉBŠw•ª–ì ‹³Žö
@r–ì@@‘×@ç—t‘åŠw ‘åŠw‰@–òŠwŒ¤‹†‰@ •ªŽq‰æ‘œ–ò•iŠwŒ¤‹†Žº ‹³Žö
@‰Y–ì@‘×Æ@“Œ‹ž‘åŠw ‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È ¶‘Ì•¨—ˆãŠwêU ˆã—p¶‘ÌHŠwuÀ ¶‘Ìî•ñ•ª–ì
@‰œ“c@“OÆ@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ¶•¨ƒvƒƒZƒXŒ¤‹†•”–å •ªŽq¶•¨HŠwŒ¤‹†ƒOƒ‹[ƒv
@‹ß]’JŽ—T@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ƒoƒCƒIƒƒfƒBƒJƒ‹Œ¤‹†•”–å Œ¤‹†•”–å’·
@L“c@Œ‰Œ›@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ƒoƒCƒIƒƒfƒBƒJƒ‹Œ¤‹†•”–å ’`”’Ž¿ƒfƒUƒCƒ“Œ¤‹†ƒOƒ‹[ƒv Œ¤‹†ƒOƒ‹[ƒv’·
@ŠÞ‘q@³Š°@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ƒoƒCƒIƒƒfƒBƒJƒ‹Œ¤‹†•”–å µãÙŒ¤‹†ˆõ
@ˆîì@~ˆê@GE ƒwƒ‹ƒXƒPƒAEƒWƒƒƒpƒ“Š”Ž®‰ïŽÐ ƒ‰ƒCƒtƒTƒCƒGƒ“ƒX“Š‡–{•” ƒoƒCƒIƒvƒƒZƒXŽ–‹Æ•”@‹Zp‰c‹Æ‰Û ƒeƒNƒjƒJƒ‹ƒGƒNƒXƒp[ƒg
@‰ª‘º@Œ³‹`@Š”Ž®‰ïŽÐƒtƒ@[ƒ}ƒgƒŠƒG ‘ã•\Žæ’÷–ð
@ŽRú±@’‰’j@’†ŠO»–òiŠ”j »–ò–{•” ¶ŽYHŠwŒ¤‹†•” »Ü‹Zp’S“– »Ü2 ƒOƒ‹[ƒvƒ}ƒl[ƒWƒƒ[
@‹T“c@Gl@Œcœä‹`m‘åŠw ˆãŠw•” “à‰ÈŠw‹³Žº ƒŠƒEƒ}ƒ`“à‰È uŽt
@’|“à@@‹Î@Œcœä‹`m‘åŠw ˆãŠw•” ƒŠƒEƒ}ƒ`“à‰È ‹³Žö
@“c’†@—ÇÆ@ŽY‹Æˆã‰È‘åŠw ˆãŠw•”‘æˆê“à‰ÈŠwuÀ ‹³Žö^ŽY‹Æˆã‰È‘åŠw•a‰@ •›‰@’·
@•ˆä@CŽ¡@Ž­Ž™“‡‘åŠw ˆãŠw•”•ÛŒ’Šw‰È ‹³Žö
@ŽOD@@@Œcœä‹`m‘åŠw ˆãŠw•”“à‰ÈŠwiÁ‰»Šíj
@¼‰ª@Ž‘P@Œcœä‹`m‘åŠw ˆãŠw•”“à‰ÈŠwiÁ‰»Šíj
@“ú”ä@‹I•¶@Œcœä‹`m‘åŠw ˆãŠw•”“à‰ÈŠwiÁ‰»Šíj ‹³Žö
@‘å“c@@Œ’@i“Æj‘—§•a‰@‹@\“Œ‹ž•a‰@ ‰@’·^’é‹ž‘åŠw ˆãŠw•”“à‰ÈŠwuÀ ŒÄ‹zŠíEƒAƒŒƒ‹ƒM[“à‰È ‹qˆõ‹³Žö
@Œã“¡@@õ@“ú–{ˆã‰È‘åŠw Ž¨•@ˆôA‰ÈŠw‹³Žº y‹³Žö
@‘å‹v•ÛŒö—T@“ú–{ˆã‰È‘åŠw Ž¨•@ˆôA‰ÈŠw‹³Žº Žå”C‹³Žö
@à_Œû@Žòl@‹à‘ò‘åŠw ‘åŠw‰@ˆã–ò•ÛŒ’Šw‘‡Œ¤‹†‰È ˆã–ò•ÛŒ’ŠwˆæˆãŠw—Þ ŒŒŠÇV¶EŒ‹‡‘gD‘ãŽÓŠw uŽt
@’ÑA@ˆèÆ@“¡“c•ÛŒ’‰q¶‘åŠw ˆãŠw•” ¬Ž™‰ÈŠw‹³Žº ‹³Žö
@Šp“c@_s@’†ŠO»–òiŠ”j Œ¤‹†–{•” ’TõŒ¤‹†•” ŽåÈŒ¤‹†ˆõ ƒOƒ‹[ƒvƒ}ƒl[ƒWƒƒ[
@‰ª•”@®•¶@’†ŠO»–òiŠ”j Ž·s–ðˆõ Œ¤‹†–{•”’·
@Γc@‚Ži@–¼ŒÃ‰®Žs—§‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰È Žîá‡E–Ɖu“à‰È uŽt —AŒŒ•”•›•”’·
@ˆÉ“¡@@ˆ®@–¼ŒÃ‰®Žs—§‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰È Žîá‡E–Ɖu“à‰È “Á”C‹³Žö
@âV“¡@Š²—Ç@’†ŠO»–òiŠ”j Œ¤‹†–{•” ‘n–òŠé‰æ„i•” •›•”’· ƒOƒ‹[ƒvƒ}ƒl[ƒWƒƒ[
@Ε@ŒhO@’†ŠO»–òiŠ”j Œ¤‹†–{•” ‘n–ò–ò—Œ¤‹†‘æ“ñ•”
@ª’Ã@~ˆê@CHUGAI PHARMABODY RESEARCH PTE LTD. RESEARCH HEAD
@ŽðŠª@‘Pt@ƒ†[ƒV[ƒr[ƒWƒƒƒpƒ“iŠ”j ŠJ”­–{•” ƒAƒ\ƒVƒGƒCƒgƒfƒBƒŒƒNƒ^[ JƒŠ[ƒ_[
@‘ºã@‘P‹I@ƒ„ƒ“ƒZƒ“ƒtƒ@[ƒ}iŠ”j Œ¤‹†ŠJ”­–{•” ƒNƒŠƒjƒJƒ‹EƒTƒCƒGƒ“ƒX“Š‡•” ƒƒfƒBƒJƒ‹ƒ‰ƒCƒeƒBƒ“ƒO•” ƒƒfƒBƒJƒ‹ƒ‰ƒCƒeƒBƒ“ƒO1G ƒOƒ‹[ƒv’·
@“¡ˆä@G“ñ@ƒ„ƒ“ƒZƒ“ƒtƒ@[ƒ}iŠ”j Œ¤‹†ŠJ”­–{•” –òŽ–“Š‡•” ‘O—Õ°ŠJ”­•” –ò—ƒOƒ‹[ƒvƒ}ƒl[ƒWƒƒ[
@ˆäì@’q”V@’†ŠO»–òiŠ”j Œ¤‹†–{•” ’TõŒ¤‹†•”
@{“¡@K•v@iŠ”jƒyƒ‹ƒZƒEƒXƒvƒƒeƒIƒ~ƒNƒX Žæ’÷–ðCTO
@•S£@•qŒõ@“Œ‹ž‘åŠw ‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È ¶‘Ì•¨—ˆãŠwêU ŠjˆãŠw•ª–ì y‹³Žö
@rˆä@‘ñ–ç@“Œ‹ž‘åŠw ‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È •úŽËüˆãŠwuÀ ŠjˆãŠw•”–å “Á”C•‹³
@–k“c@FK@“Œ‹ž‘åŠw ‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È ¶‘Ì•¨—ˆãŠwêU ŠjˆãŠw•ª–ì
@“¡’J@GÍ@“Œ‹ž‘åŠw æ’[‰ÈŠw‹ZpŒ¤‹†ƒZƒ“ƒ^[ ƒVƒXƒeƒ€¶•¨ˆãŠw “Á”C‹³Žö
@“ú–ì@’q–ç@’¹Žæ‘åŠw ‘åŠw‰@HŠwŒ¤‹†‰È ‰»ŠwE¶•¨‰ž—pHŠwêU ¶•¨HŠwŒ¤‹†Žº
@Šâ“c@@‘z@‹ž“s‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰È •ªŽq×–Eî•ñŠw
@‘º“c@•Žm@ç—t‘åŠw ‘åŠw‰@—ŠwŒ¤‹†‰È “Á”Cy‹³Žö
@‘å“à@@@’†ŠO»–òiŠ”j ‘n–ò–ò—Œ¤‹†‘æ‚Q •” Šà‚R ƒOƒ‹[ƒv ŽåŠ²Œ¤‹†ˆõ
@Γc@@W@–kŠC“¹‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰È Šá‰ÈŠw•ª–ì ‰ŠÇŠá‰ÈŠwuÀEŠázŠÂ‘ãŽÓŠwuÀ ‹³Žö
@‘Oì@^l@•l¼ˆã‰È‘åŠw —Õ°ŒŸ¸ˆãŠwuÀ ‹³Žö
@ŒK@@Ž•F@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š Œv‘ª•W€Œ¤‹†•”–å ƒoƒCƒIƒƒfƒBƒJƒ‹•W€Œ¤‹†Žº‹qˆõŒ¤‹†ˆõ
@“¡“c@´‹M@ŒQ”nƒp[ƒX‘åŠw •ÛŒ’‰ÈŠw•” ŒŸ¸‹ZpŠw‰È€”õŽº’· ‹³Žö
@‹TŽq@•¶Žq@MB‘åŠw ˆãŠw•”•ÛŒ’Šw‰È ŒŸ¸‹Zp‰ÈŠwêU •‹³
@“Œ@@Ž–¤@ˆÇ—Ñ‘åŠw ‘åŠw‰@•ÛŒ’ŠwŒ¤‹†‰È ‹³Žö
@ŒÜ“‡@’¼Ž÷@i“ÆjŽY‹Æ‹Zp‘‡Œ¤‹†Š ƒoƒCƒIƒƒfƒBƒVƒiƒ‹î•ñŒ¤‹†ƒZƒ“ƒ^[iBIRCj ×–EƒVƒXƒeƒ€§Œä‰ð̓`[ƒ€ Žå”CŒ¤‹†ˆõ
@‘q‘ò@˜aG@àÕ‹¦ˆã‰È‘åŠw ŒÄ‹zŠíEƒAƒŒƒ‹ƒM[“à‰È y‹³Žö
@ûüè@–F¬@‡“V“°‘åŠw ˆãŠw•”äPŒ´•a“à‰È ‹³Žö
@àVˆä@@Û@ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ •ªŽq•a‘Ô‰ðÍŠw
@ŒKŒ´@@‘@ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ _Œo“à‰ÈŠw ‹³Žö
@–쑺@•¶•v@ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ •ªŽq•a‘Ô‰ðÍŠw ‹³Žö
@“Þ—Ç@½l@ŒQ”n‘åŠw ˆãŠw•”•‘®•a‰@ Š´õ§Œä•” •‹³
@‘ºã@³–¤@ŒQ”n‘åŠw ‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È —Õ°ŒŸ¸ˆãŠw ‹³Žö
@“¡“c@^–ç@ŠÖ¼ˆã‰È‘åŠw “à‰ÈŠw‘æˆêuÀ
@–쑺@¹ì@ŠÖ¼ˆã‰È‘åŠw “à‰ÈŠw‘æˆêuÀ Žå”C‹³Žö
@‘K’J@Š²’j@“Œ‹žŽœŒb‰ïˆã‰È‘åŠw ‘åŠw‰@Á‰»Ší“à‰ÈŠw ‹³Žö
@“‡“c@‰pº@“Œ–M‘åŠw ŠO‰ÈŠwuÀ ˆê”ÊEÁ‰»ŠíŠO‰È ‹³Žö
@’J“‡@@‘@“Œ–M‘åŠw ŠO‰ÈŠwuÀ ˆê”ÊEÁ‰»ŠíŠO‰È
@‘哈@—zK@“Œ–M‘åŠw ŠO‰ÈŠwuÀ ˆê”ÊEÁ‰»ŠíŠO‰È
@¬’r@~ˆê@“Œ–M‘åŠw ŠO‰ÈŠwuÀ ˆê”ÊEÁ‰»ŠíŠO‰È
@–¼”g@—³‹K@“Œ–M‘åŠw ŠO‰ÈŠwuÀ ˆê”ÊEÁ‰»ŠíŠO‰È
@ΊÛ@@Œ’@–kŠC“¹Ô\ŽšŒŒ‰tƒZƒ“ƒ^[ ŒŸ¸•” ŒŸ¸ˆê‰Û ŒŸ¸“ñŒW’·
@²“¡iˆê˜Y@–kŠC“¹Ô\ŽšŒŒ‰tƒZƒ“ƒ^[ ŒŸ¸•”’·
@’r“c@‹v›‰@–kŠC“¹Ô\ŽšŒŒ‰tƒZƒ“ƒ^[ –¼—_Š’·
@ˆÉ“¡@_–¾@‚ ‚¢‚¿¬Ž™•ÛŒ’ˆã—чƒZƒ“ƒ^[ “à‰È•”’·
@²“¡@•K@ç—t‘åŠw ˆãŠw•”•‘®•a‰@ Š´õÇŠÇ—Ž¡—Õ” •”’·
@¼–{@“NÆ@“Œ‹žˆã‰È‘åŠw ”÷¶•¨ŠwuÀ Žå”C‹³Žö^“Œ‹žˆã‰È‘åŠw•a‰@ Š´õ§Œä•” •”’·
@Θa“c–«•F@ç—t‘åŠw ˆãŠw•”•‘®•a‰@ Š´õÇŠÇ—Ž¡—Õ” uŽt
@‹Tˆä@Ž•F@ç—t‘åŠw ^‹ÛˆãŠwŒ¤‹†ƒZƒ“ƒ^[ —Õ°Š´õÇ•ª–ì
@“n•Ó@@“N@ç—t‘åŠw ˆãŠw•”•t‘®•a‰@ Š´õÇŠÇ—Ž¡—Õ”
@t–Ø@G‰î@“Æ‹¦ˆã‰È‘åŠw ‰z’J•a‰@ —Õ°ŒŸ¸•” ‹³Žö
@’|Œ´@ˆê–¾@“Œ‹ž”_H‘åŠw ‘åŠw‰@”_ŠwŒ¤‹†‰@ “®•¨¶–½‰ÈŠw•”–å ‹³Žö
@_Œ´@—R‹G@ƒƒVƒ…Eƒ_ƒCƒAƒOƒmƒXƒeƒBƒbƒNƒXŠ”Ž®‰ïŽÐ TD Ž–‹Æ•” ŠwpEƒ}[ƒPƒeƒBƒ“ƒO•”
@ŠÝ@@Œ\‰î@ƒ†[ƒV[ƒr[ƒWƒƒƒpƒ“iŠ”j ŠJ”­–{•”–òŽ–•” ƒfƒBƒŒƒNƒ^[
@ìè@ƒiƒi@‘—§ˆã–ò•iH•i‰q¶Œ¤‹†Š ¶•¨–ò•i•”’·
@ìã@_Ži@‹ž“s‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰È –ò܉uŠw•ª–ì —Ž–•âE‹³Žö
@ŒË@Æ¢@i“Æjˆã–ò•iˆã—Ë@Ší‘‡‹@\ ƒŒƒMƒ…ƒ‰ƒgƒŠ[ƒTƒCƒGƒ“ƒX„i•”Œ¤C‰ÛŒ¤C‰Û’·
@ŽRŒû@Ɖp@‘—§ˆã–ò•iH•i‰q¶Œ¤‹†Š ¶•¨–ò•i•”Œ¤‹†ˆõ
@Ž™‹Ê@‹`Ÿ@iŠ”jƒC[ƒ_ƒuƒ‹ƒjƒ…[ƒgƒŠƒVƒ‡ƒ“EƒWƒƒƒpƒ“ Šò•Œ–ƉuŒ¤‹†Š ‹ZpŒÚ–â
@•À–Ø@G’j@‘ˆî“c‘åŠw ‹³ˆçE‘‡‰ÈŠwŠwp‰@ ¶•¨Šw‹³Žº ‘åŠw‰@æi—HŠwŒ¤‹†‰È ¶–½—HŠwêU ‹³Žö
@¬àV@@’q@ƒ_ƒCƒLƒ“H‹ÆiŠ”j ƒeƒNƒmƒƒW[EƒCƒmƒx[ƒVƒ‡ƒ“ƒZƒ“ƒ^[Ý—§€”õŽº ƒCƒmƒx[ƒVƒ‡ƒ“Šé‰æ’S“–‰Û’·
@
V‹@”\R‘ÌŠJ”­ƒnƒ“ƒhƒuƒbƒN
Handbook of Therapeutic and Diagnostic Antibodies
Copyright@(C) 2012@NTS Inc. All right reserved.
@